Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Richmond Pharmacology highlights encouraging first-in-human results for Regeneron's investigational RNAi therapy in MASLD

12
November 2026

NEJM publication and AASLD presentation reports that 79% of treated participants with MASLD and available measurements achieved normal liver fat levels at Week 24 after a single dose of CIDEBsiRNA, alongside improvements in markers of liver injury.

View Article

The Future of Cardiometabolic Research: Five Questions Shaping the Next Decade

22
October 2026

Cardiometabolic research is continually evolving beyond explanations centred on single causes of disease.

View Article

Richmond Pharmacology Appoints Adam Hurd as Operations Director

17
August 2026

Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Adam Hurd as Operations Director

View Article

Celebrating 25 Years of Richmond Pharmacology

13
August 2026

For 25 years, Richmond Pharmacology has been helping sponsors translate scientific discovery into early phase clinical research.

View Article

Latest article from our Director of Regulatory Strategy & Pharmacovigilance

11
August 2026

We’re pleased to share the latest article from our Director of Regulatory Strategy & Pharmacovigilance, Dr Lisa Campbell

View Article

Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director

13
July 2026

Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.

View Article

Latest news

Richmond Pharmacology highlights encouraging first-in-human results for Regeneron's investigational RNAi therapy in MASLD

November 12, 2026
NEJM publication and AASLD presentation reports that 79% of treated participants with MASLD and available measurements achieved normal liver fat levels at Week 24 after a single dose of CIDEBsiRNA, alongside improvements in markers of liver injury.
Read more

Upcoming Event

AHA Scientific Sessions 2026

14 - 16 November 2026
Richmond Pharmacology is excited to join the AHA Scientific Sessions 2026 in 14–16 November 2026, on 14–16 November 2026, hosted by the American Heart Association.
View event